OTCM
ELOX
Market cap0kUSD
Mar 26, Last price
0.00USD
Name
Eloxx Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
77.08%
Rev. gr., 5y
%
Revenues
0k
Net income
-36m
L-45.95%
CFO
-32m
L-9.02%
Profile
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2017‑06 | 2016‑06 | 2015‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 34,419 | ||||||||
Unusual Expense (Income) | |||||||||
NOPBT | (34,419) | ||||||||
NOPBT Margin | |||||||||
Operating Taxes | 2,026 | ||||||||
Tax Rate | |||||||||
NOPAT | (36,445) | ||||||||
Net income | (36,065) -45.95% | ||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 4,692 | ||||||||
Long-term debt | 9,539 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (4,976) | ||||||||
| Cash flow | |||||||||
Cash from operating activities | (31,845) | ||||||||
CAPEX | (66) | ||||||||
Cash from investing activities | (66) | ||||||||
Cash from financing activities | 8,812 | ||||||||
FCF | (35,780) | ||||||||
| Balance | |||||||||
Cash | 19,207 | ||||||||
Long term investments | |||||||||
Excess cash | 19,207 | ||||||||
Stockholders' equity | (274,366) | ||||||||
Invested Capital | 277,090 | ||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 2,166 | ||||||||
Price | 1.82 157.72% | ||||||||
Market cap | 3,943 219.20% | ||||||||
EV | (1,033) | ||||||||
EBITDA | (33,724) | ||||||||
EV/EBITDA | 0.03 | ||||||||
Interest | 1,949 | ||||||||
Interest/NOPBT | |||||||||